The U.S. Department of Justice charged Novartis’ Sandoz unit with conspiring to allocate customers, rig bids, and fix prices for generic drugs. The charged conspiracies took place between 2013 and 2015. Sandoz admitted that it participated in the charged antitrust conspiracies with regard to the following drugs: clobetasol (cream, emollient cream, gel, ointment, and solution), desonide ointment, nystatin triamcinolone cream, benazepril HCTZ, and tobramycin inhalation solution. The company entered into a deferred prosecution agreement with the government and paid a $195 million criminal penalty to resolve the charges.